A Novel Therapeutic

We’re creating the first potential treatment for Demodex blepharitis

What is TP-03?

TP-03 is a novel therapeutic that may offer treatment, if approved, for millions of patients with Demodex blepharitis.

Potentially 25 million patients with Demodex blepharitis in the US have been left without an FDA-approved treatment.

TP-03 can change that.

The active ingredient in TP-03 is lotilaner, a well characterized anti-parasitic agent that targets parasite-specific GABA-CI channels.

Clinical Summary

Mars Study
Presented by Roberto Gonzalez-Salinas, M.D., Ph.D. at ARVO 2020 Virtual Meeting.
Mars and Jupiter Studies
Presented by Paul Karpecki, OD, FAAO at AAOPT 2020 Virtual Meeting.
Io and Europa Studies
Presented by Roberto Gonzalez-Salinas, M.D., Ph.D. on October 6, 2020.
Contact Tarsus

Please reach out to us using the form below.

General Information
Investor Relations
Opt in to be the first to receive the latest Tarsus news
Contact Tarsus

Thank you for getting in touch! Someone from our team will respond shortly.